An interventional study of Standard Medical Care with an Obesity Management Medication and Cardiovascular Exercise Training in Obesity & Overweight, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Obesity by University of Kansas Medical Center — 9 open to participants now, 9 under way, none of them phase 3. Obesity · University of Kansas Medical Center.
Among the 32 studies in Obesity by University of Kansas Medical Center, this one is the 7th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2026, is one of 28 with no phase, and was the 31st registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →9 of the 32 studies in Obesity by University of Kansas Medical Center are open now, in 1 country. Recruiting first, the newest first:
University of Kansas Medical Center · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
University of Kansas Medical Center · Sites in United States
Ages 18–35
University of Kansas Medical Center · Sites in United States
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 198 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 60 across the 29 interventional studies, 60 across the 3 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Kansas Medical Center is the lead sponsor of 493 studies on the registry; 111 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
2 of the studies in Obesity by University of Kansas Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06640179University of Kansas Medical CenterFeasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL) | 2027-02-01 |
| NCT05985486University of Kansas Medical CenterBrain Outcomes With Lifestyle Change in Down Syndrome | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Obesity by University of Kansas Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether adding either cardiovascular exercise or resistance exercise to pharmacotherapy treatment for obesity improves the retention of lean mass compared to pharmacotherapy alone in adults with overweight or obesity who are prescribed pharmacotherapy for obesity treatment by their personal physician. It will also provide information about whether either form of exercise added to pharmacotherapy for obesity treatment has additional benefits on other health and fitness measurements. The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive standard medical care from their personal physician related to their obesity management medication for a period of 6 months. Progression of this medication will be monitored as part of the participation in this study. Participants will undergo screening and baseline assessments prior to initiating the use of the medication and after a period of 6 months. Upon randomization, participants will receive a "Nutrition 101" session where dietary considerations while taking this medication will be discussed. We will also have a brief contact (weeks 3, 6, 9, 12, 15, 18, and 21) with the participant to monitor changes in weight, blood pressure, health status, and medication adherence and use (including the dose of the obesity management medication that they have been prescribed). Participants will be instructed to maintain their current level of physical activity throughout the 6-month study period.
Other: Standard Medical Care with an Obesity Management Medication · Behavioral: Nutrition Counseling
Participants will receive the same standard of care as described for the "Standard Care with an Obesity Management Medication" condition; however, participants will also engage in supervised cardiovascular exercise training. This will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, we will allow for alternative forms of cardiovascular exercise (upright or recumbent cycling, elliptical, etc.) to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.
Other: Standard Medical Care with an Obesity Management Medication · Behavioral: Cardiovascular Exercise Training · Behavioral: Nutrition Counseling
Participants will receive the same standard of care as described for the "Standard Care with an Obesity Management Medication" condition; however, participants will also engage in supervised resistance exercise training. This will occur 3 days per week and involve 9 different exercises. Each exercise will progress to 3 sets with a rest period of 60 to 90 seconds between each set. Warm-up sets will include 10 repetitions, and all remaining sets will perform repetitions until volitional fatigue. Heart rate will be monitored throughout these exercise sessions.
Other: Standard Medical Care with an Obesity Management Medication · Behavioral: Resistance Exercise Training · Behavioral: Nutrition Counseling
Participant will receive standard medical care that includes the prescription and titration of a study eligible obesity management medication.
Participant will receive supervised cardiovascular exercise training on 3 days per week for a period of 6 months.
Participant will receive supervised resistance exercise training on 3 days per week for a period of 6 months.
Participant will receive brief nutrition counseling specific to obesity managment medications after randomization for this study.
Lean body mass
Lean Body Mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).
Time frame: 0 and 6 months
Muscle Mass
Muscle Mass (kg) will be assessed using the deuterated creatine (D3Cr) dilution method.
Time frame: 0 and 6 months
Muscle Quality
Muscle quality will be assessed using magnetic resonance imaging (MRI) of the mid-thigh.
Time frame: 0 and 6 months
Body Weight
Body weight will be assessed in duplicate using a calibrated digital scale to the nearest 0.1 kg.
Time frame: 0 months, week 6, week 12, week 18, 6 months
Body Mass Index
Measurements of weight and height will be used to compute BMI (kg/m2).
Time frame: 0 months, week 6, week 12, week 18, 6 months
Percent body fat
Percent body fat will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).
Time frame: 0 and 6 months
Body Fat Mass
Body fat mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).
Time frame: 0 and 6 months
Bone mineral content
Bone mineral content (grams) will be assessed using total body, femur, and spine scans from dual-energy x-ray absorptiometry (DXA).
Time frame: 0 and 6 months
Bone mineral density
Bone mineral density (g/cm2) will be assessed using total body, femur, and spine scans from dual-energy x-ray absorptiometry (DXA).
Time frame: 0 and 6 months
Bone Biomarkers
Bone biomarkers will be assessed from blood samples collected using venipuncture.
Time frame: 0 and 6 months
Waist Circumference
Circumference measures of the waist will be taken horizontally at both the iliac crest and the umbilicus.
Time frame: 0 and 6 months
Hip Circumference
Circumference measures of the hip will be taken horizontally at the widest observed portion of the buttocks.
Time frame: 0 and 6 months
Cardiorespiratory Fitness
Cardiorespiratory fitness will be represented as milliliters of oxygen consumed per kilogram of body weight per minute (ml/kg/min) measured with a metabolic cart during a submaximal graded exercise test that is terminated when the participant achieves 85% of age-predicted maximal heart rate or if taking a medication that will impact heart rate response to exercise, then achieving a Rating of Perceived Exertion (RPE) of 16 on the 6-20 scale.
Time frame: 0 and 6 months
Cardiorespiratory Fitness
Cardiorespiratory fitness will be represented as total liters of oxygen consumed per minute (L/min) measured with a metabolic cart during a submaximal graded exercise test that is terminated when the participant achieves 85% of age-predicted maximal heart rate or if taking a medication that will impact heart rate response to exercise, then achieving a Rating of Perceived Exertion (RPE) of 16 on the 6-20 scale.
Time frame: 0 and 6 months
Cardiorespiratory Fitness
Cardiorespiratory fitness will be the duration measured in minutes to achieve 85% of age-predicted maximal heart rate during a submaximal graded exercise test performed on a treadmill or if taking a medication that will impact heart rate response to exercise, then achieving a Rating of Perceived Exertion (RPE) of 16 on the 6-20 scale.
Time frame: 0 and 6 months
Muscle Strength
Muscular strength will be measured from an isometric leg extension performed on a dynamometer.
Time frame: 0 and 6 months
Physical Function
Physical function will be measured using the Short Physical Performance Protocol (SPPB) that includes balance, gait speed, and chair stands).
Time frame: 0 and 6 months
Muscle Power
Muscle Power is measured using the Margaria Power Stair Climb Task that requires the participant to walk up a standardized flight of stair, with the score being the time it takes to walk from the 3rd step to the 9th step. A faster time at a given body mass indicates a greater level of muscle power.
Time frame: 0 and 6 months
Health-Related Quality of Life
Health-related quality of life is assessed with a standardized questionnaire. This questionnaire consists of 8 scales (physical functioning, role limitations caused by health problems, role limitation caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, general health perceptions) with each scale score between 0-100. This also consists of 2 subscales (physical and mental health) with these being scored as the average of the scores from the scales that are factored into each measure. This also provides an overall score, which is the average of the scores for each of the 8 scales. A higher score on a scale or subscale indicates a higher health-related quality of life.
Time frame: 0 and 6 months
Energy Intake (Dietary Intake)
Energy Intake (Dietary Intake) expressed as kilocalories eaten per day (kcal/day) will be measured using the Diet History Questionnaire (DHQ) developed by NCI. A higher score represents more calories eaten.
Time frame: 0 months, week 6, week 12, week 18, 6 months
Energy Intake (Dietary Intake)
Energy Intake (Dietary Intake) expressed as kilocalories eaten per day (kcal/day) will be measured using a 3-day dietary recall (2 weekdays and 1 weekend day). A higher score represents more calories eaten.
Time frame: 0 months, week 6, week 12, week 18, 6 months
Physical Activity
Physical activity will be measured using the Physical Activity and Exercise Questionnaire. A higher score represents more physical activity expressed as minutes per week or calories of energy expenditure per week.
Time frame: 0 and 6 months
Physical Activity
Physical activity will be measured using the Global Physical Activity Questionnaire (GPAQ). A higher score represents more physical activity expressed as minutes per week or calories of energy expenditure per week.
Time frame: 0 and 6 months
Physical Activity
Physical activity will be measured Garmin wrist worn activity tracker that will be provided to each participant to wear throughout the entire 6 month intervention period. A higher score represents more physical activity.
Time frame: 0 and 6 months
Medication Reporting
A questionnaire developed specifically for this study will be used to assess medication history and use of prescribed obesity management medications. The data collected include the type of medication, dose of medication, and frequency that the medication is taken, and what condition the medication is indicated to treat.
Time frame: 0 and 6 months, and weeks 3, 6, 9, 12, 15, 18, 21
Obesity Management Medication Adherence
A questionnaire developed specifically for this study will be used to assess adherence to the prescribed obesity management medications. The data collected include the type of medication, dose of medication, and frequency that the medication is taken.
Time frame: 0 and 6 months, and weeks 3, 6, 9, 12, 15, 18, 21
Demographic Characteristics
A questionnaire developed specifically for this study will be used to assessment demographic characteristics (age, sex, race, etc.).
Time frame: 0 months
Lifestyle and Health History
A questionnaire developed specifically for this study that is conducted as an interview will be used to assess lifestyle and health factors to describe the sample for this study. The score is either "yes" or "no" identifying the presences of a lifestyle or health factor.
Time frame: 0 months (prior to randomization)
Adverse and Serious Adverse Events
Participants will be queried using a survey developed specifically for this study will be used to assess for adverse events and serious adverse events.
Time frame: 0 and 6 months, and weeks 3, 6, 9, 12, 15, 18, 21 and at other times when reported by the participant
Plan to share: Yes — The summary data for each of the study outcomes and other additional demographic characteristics will be made available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: The data will be made available no later than the time of an associated publication of study outcomes or at the end of the performance period, whichever comes first. The data provided to the repository will be available indefinitely while that repository continues to exist.
Access criteria: The information included with the IPD will be made available to appropriate individuals only after the requester confirms their willingness to comply with an appropriate "Data Use Agreement" that complies with NIH policies, the policies of the institution where the study has been conducted, and the elements of informed consent.
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Mar 2030, 44 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 44 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kansas Medical Center →